Corvus Pharmaceuticals, Inc. Financing Cash Flow
Corvus Pharmaceuticals, Inc. (CRVS) reported Financing Cash Flow of $190.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $166.00K, a 99.54% decline year-over-year.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $190.75M, a 68267.74% increase year-over-year.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $20.00K, a 99.89% decline year-over-year.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $360.00K, a 620.00% increase year-over-year.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $36.43M, a 25.70% decline from fiscal 2024.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $49.03M, a 524.16% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $7.86M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $190.91M 10-Q · filed 2026-08-06 | $190.93M derived: sum of 3 quarters · filed 2026-08-06 | $191.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $190.75M 10-Q · filed 2026-05-07 | $190.77M derived: sum of 2 quarters · filed 2026-05-07 | $191.13M derived: sum of 3 quarters · filed 2026-05-07 | $226.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $380.00K derived: sum of 2 quarters · filed 2026-03-12 | $36.15M derived: sum of 3 quarters · filed 2026-08-06 | $36.43M 10-K · filed 2026-03-12 |
| 2025-09-30 | $360.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $36.13M derived: sum of 2 quarters · filed 2026-08-06 | $36.41M 10-Q · filed 2025-11-04 | $55.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $35.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $36.05M 10-Q · filed 2026-08-06 | $54.66M derived: sum of 3 quarters · filed 2026-08-06 | $54.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $279.00K 10-Q · filed 2026-05-07 | $18.89M derived: sum of 2 quarters · filed 2026-05-07 | $18.94M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $18.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $18.66M derived: sum of 2 quarters · filed 2026-03-12 | $49.03M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $30.42M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $30.37M 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $335.00K derived: sum of 2 quarters · filed 2026-03-12 | $7.85M derived: sum of 3 quarters · filed 2026-03-12 | $7.86M 10-K · filed 2026-03-12 |
| 2023-09-30 | $335.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.85M derived: sum of 2 quarters · filed 2024-11-12 | $7.86M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $7.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $7.52M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $4.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-25 | |||
| 2021-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $18.35M derived: sum of 2 quarters · filed 2024-03-19 | $29.57M derived: sum of 3 quarters · filed 2024-03-19 | $62.16M 10-K · filed 2024-03-19 |
| 2021-09-30 | $18.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $29.55M derived: sum of 2 quarters · filed 2022-11-03 | $62.14M 10-Q · filed 2022-11-03 | $63.36M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $11.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $43.81M 10-Q · filed 2022-08-08 | $45.03M derived: sum of 3 quarters · filed 2023-03-28 | $45.09M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $32.59M 10-Q · filed 2022-05-05 | $33.81M derived: sum of 2 quarters · filed 2023-03-28 | $33.88M derived: sum of 3 quarters · filed 2023-03-28 | |
| 2020-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $1.29M derived: sum of 2 quarters · filed 2023-03-28 | $1.31M 10-K · filed 2023-03-28 | |
| 2020-09-30 | $64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $87.00K 10-Q · filed 2021-11-01 | ||
| 2020-06-30 | $23.00K 10-Q · filed 2021-08-02 | |||
| 2019-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $18.00K derived: sum of 2 quarters · filed 2022-03-10 | $23.00K derived: sum of 3 quarters · filed 2022-03-10 | $24.00K 10-K · filed 2022-03-10 |
| 2019-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $21.00K derived: sum of 2 quarters · filed 2020-10-29 | $22.00K 10-Q · filed 2020-10-29 | $194.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $6.00K 10-Q · filed 2020-07-30 | $178.00K derived: sum of 3 quarters · filed 2021-03-25 | $344.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $1.00K 10-Q · filed 2020-04-30 | $173.00K derived: sum of 2 quarters · filed 2021-03-25 | $339.00K derived: sum of 3 quarters · filed 2021-03-25 | $387.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $338.00K derived: sum of 2 quarters · filed 2021-03-25 | $386.00K derived: sum of 3 quarters · filed 2021-03-25 | $65.27M 10-K · filed 2021-03-25 |
| 2018-09-30 | $166.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $214.00K derived: sum of 2 quarters · filed 2019-10-29 | $65.10M 10-Q · filed 2019-10-29 | $66.41M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $64.93M 10-Q · filed 2019-08-01 | $66.24M derived: sum of 3 quarters · filed 2020-03-09 | $66.37M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-03-31 | $64.88M 10-Q · filed 2019-05-09 | $66.19M derived: sum of 2 quarters · filed 2020-03-09 | $66.32M derived: sum of 3 quarters · filed 2020-03-09 | $66.32M derived: sum of 4 quarters · filed 2020-03-09 |
| 2017-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $1.43M derived: sum of 2 quarters · filed 2020-03-09 | $1.43M derived: sum of 3 quarters · filed 2020-03-09 | $1.44M 10-K · filed 2020-03-09 |
| 2017-09-30 | $126.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $126.00K derived: sum of 2 quarters · filed 2018-11-01 | $134.00K 10-Q · filed 2018-11-01 | $137.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $8.00K 10-Q · filed 2018-08-02 | $11.00K derived: sum of 3 quarters · filed 2019-03-07 | $11.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $8.00K 10-Q · filed 2018-05-03 | $11.00K derived: sum of 2 quarters · filed 2019-03-07 | $11.00K derived: sum of 3 quarters · filed 2019-03-07 | |
| 2016-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $3.00K derived: sum of 2 quarters · filed 2019-03-07 | $71.36M 10-K · filed 2019-03-07 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $71.36M 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $71.36M 10-Q · filed 2017-08-03 | |||
| 2015-12-31 | $94.95M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |